Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Damaged mucosal proteins refer to the proteinaceous exudate, primarily consisting of albumin, fibrinogen, and globulins, that is exposed at the site of gastrointestinal mucosal injury such as ulcers or erosions (StatPearls, 2023). These proteins serve as a localized therapeutic target for cytoprotective agents, most notably sucralfate and bismuth-containing compounds (DrugBank, 2024). In an acidic environment, sucralfate undergoes polymerization to form a negatively charged, viscous paste that binds to the positively charged proteins within the damaged tissue (PubChem, 2024). This interaction creates a physical barrier that shields the underlying mucosa from the corrosive effects of gastric acid, pepsin, and bile salts, thereby promoting tissue repair and healing. While not a single molecular entity, this protein complex is a well-recognized pharmacological target in the treatment of acid-peptic disorders.
Formation of a physical cytoprotective barrier through ionic binding to exposed proteins at the site of mucosal injury.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Damaged mucosal proteins.